Abstract:Abstract Lung cancers represent the second most common cancer and Non-Small Cell Lung Cancer (NSCLC) constitutes 80-85% of all lung cancers. Genes within several cellular pathways have been previously evaluated for their clinical impact in NSCLC. In this investigation, we evaluate genetic mutations found in 50 cancer-critical genes implicated in the signaling pathways RTK/RAS/MAP, TGFβ, PI3K, Wnt, GPCR, p53, JAK/STAT, Notch, and the cell cycle pathway. Some of these mutations have not yet been described or have not been described in NSCLC. The intent of our study is to evaluate these mutations and allow further research into their impact, specifically highlighting mutations that are involved in clinically important pathways. We evaluated mutations found in 59 NSCLC patients at the Prisma Health Cancer Institute. These mutations are part of 2,800 COSMIC (Catalogue of Somatic Mutations in Cancer) hotspot mutations in 50 cancer-critical genes. Each mutation was investigated further using the ClinVar database to identify whether it had been described in NSCLC or other cancers/conditions, its genetic consequence, pathogenesis, possible variations, and origin. A total of 73 unique mutations in 59 NSCLC patients were evaluated. Of the 73 mutations, 17 had not been described at all, 40 had been described in other cancers/conditions, and 16 had been previously described in NSCLC. The known mutations’ effects in other cancers/conditions were categorized as pathogenic, likely pathogenic, likely benign, benign, or uncertain. Novel mutations were found in genes that provide a druggable target, help predict treatment response, are under investigation for their ability to predict treatment response or confer additional clinical utility. Medical management of cancer has benefitted greatly from studies of genetic mutations. Most mutations identified in our patient population had not been described in NSCLC, and a smaller number of those had not been described at all. Further elucidation of these mutations may lead to additional discoveries relevant to NSCLC prognostication and treatment. Citation Format: Miles Rothstein, Phillip Broughton, Ella Markalunas, Avery Funkhouser, Lorie Allen, Julie Martin, W. Jeffery Edenfield, Anna V. Blenda. Evaluation of genetic mutations in non-small cell lung cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5062.

Clinical Study Of Baseline Characteristics And Gene Mutation Spectrum Of Non-Small-Cell Lung Cancer Patients With Tuberculosis

Combined Effects of Cigarette Smoking, Gene Polymorphisms and Methylations of Tumor Suppressor Genes on Non Small Cell Lung Cancer: a Hospital-Based Case-Control Study in China

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Relationship between EGFR mutation and pulmonary tuberculo-sis in lung adenocarcinoma patients

Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country

The burden of tuberculosis among patients with non-small cell lung carcinoma in a tertiary care center

362P Integrative and Comparative Genomic Analysis and Immune Microenvironment Features of Lung Cancer Patients with Tuberculosis

Prognostic factors for survival in a Chinese population presenting with advanced non-small cell lung cancer with an emphasis on smoking status: A regional, single-institution, retrospective analysis of 4552 patients

P1.03-03 Molecular Characteristics of Chinese Patients with TSC2-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

The Diagnosis Interval Influences Risk Factors of Mortality in Patients with Co-Existent Active Tuberculosis and Lung Cancer: a Retrospective Study.

Prevalence of Targeted Therapy-Related Genetic Variations in NSCLC and Their Relationship with Clinicopathological Characteristics

Impact of Historic Tuberculosis on CT Evaluation of Lymph Node Staging in NSCLC Patients

Clinical characteristics and gene mutation profiles of chronic obstructive pulmonary disease in non-small cell lung cancer

Catalog of Lung Cancer Gene Mutations Among Chinese Patients

Clinical and molecular characteristics of TSC1/2 mutant lung cancer.

Prevalence and Clinical Significance of Pathogenic Germline BRCA1/2 Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Abstract 5062: Evaluation of genetic mutations in non-small cell lung cancer patients

Prevalence and Clinical Profile of EGFR Mutation in Non- Small-Cell Lung Carcinoma Patients in Southwest China.

Analysis of the clinicopathological features of 721 cases with NSCLC

BRAF/ KRAS and PIK3CA mutation characteristics and clinical significance in primary small cell lung caner